Ratha Mahendran

Mahendran Ratha

  • Senior Research Fellow, Department of Surgery
Administrative Appointment(s)
  • Member, Institutional Biosafety Committee, National University of Singapore
  • Member, MD4 & MD11 Central Research Facilities Safety Committee, NUS Yong Loo Lin School of Medicine
  • Member, NUHS Internal Grants Review Committee
Academic Qualifications
  • PhD, University of Texas at Dallas, USA
  • BSc (Honours), National University of Singapore, Singapore
Research Interest(s)
  • Bladder Cancer
  • Immunotherapy
  • SNPs
  • BCG
  • Animal Models
Recent Publications
  • 1. Lu S, Neoh KG, Kang ET, Mahendran R, Chiong E. 2015 May. Mucoadhesive polyacrylamide nanogel as a potential hydrophobic drug carrier for intravesical bladder cancer therapy. Eur J Pharm Sci. 72:57-68. doi: 10.1016/j.ejps.2015.03.006. 25772330.
  • 2. Chan EC, Pasikanti KK, Hong Y, Ho PC, Mahendran R, Raman Nee Mani L, Chiong E, Esuvaranathan K. 2015 Feb. Metabonomic profiling of bladder cancer. J Proteome Res. 14(2):587-602. doi: 10.1021/pr500966h. 25388527.
  • 3. Zhang Q, Neoh KG, Xu L, Lu S, Kang ET, Mahendran R, Chiong E. 2014 Jun. Functionalized mesoporous silica nanoparticles with mucoadhesive and sustained drug release properties for potential bladder cancer therapy. Langmuir. 30(21):6151-61. doi: 10.1021/la500746e. 24824061.
  • 4. 2014 Mar. Association of natural resistance-associated macrophage protein 1 (NRAMP1) polymorphisms with response to BCG immunotherapy for non-muscle invasive bladder cancer. BJU International. 113.
  • 5. R. Mahendran, S.M. Tham, J.N. Rahmat, Y.K. Lim, J.H. Sng, L.N. Raman, Z.M.W. Ma, W.C. Tsang, E. Chiong, Y.H. Chan, K. Esuvaranathan. 2014 Apr. CTLA4 single nucleotide polymorphisms correlate with response to BCG immunotherapy. The Journal of Urology. 191(4):e364. 10.1016/j.juro.2014.02.1021.